The delisting risk is resolved for now, but the company still faces ongoing Nasdaq listing requirements and must demonstrate compliance at its next 10-K filing. Monitor the Q4 2026 10-K for stockholders' equity levels and any further financing needs.
Price Chart
Executive Summary
Alaunos Therapeutics received Nasdaq confirmation that it has regained compliance with the $2.5M minimum stockholders' equity requirement following its October 14 private placement financing. The delisting hearing scheduled for November 10, 2026 has been cancelled, and TCRT common stock will continue trading on the Nasdaq Capital Market. This removes the immediate delisting overhang for this $11M market-cap biotech.
Key Facts
- Nasdaq confirmed on October 22, 2026 that Alaunos has regained compliance with the $2,500,000 minimum stockholders' equity requirement (Listing Rule 5550(b)(1)).
- The delisting hearing before the Nasdaq Hearings Panel scheduled for November 10, 2026 has been cancelled.
- Compliance was achieved through the completion of a private placement financing on October 14, 2026.
- The company had been out of compliance since an initial deficiency notice on April 9, 2026.
Financial Impact
Removes delisting risk for TCRT common stock; no specific dollar amount of equity restored disclosed in this filing.
Risk Factors
- The company warns that if it does not evidence compliance at the time of its Annual Report on Form 10-K for fiscal year ending December 31, 2026, it may still be subject to delisting.
- Operating losses and transaction costs continue to erode stockholders' equity, requiring future financings or operational milestones to maintain compliance.
- Preliminary accounting conclusions regarding preferred stock classification may change upon audit review.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-430507 |
| Document: 0001193125-26-430507-index-headers.html | 0001193125-26-430507 |
| Document: 0001193125-26-430507-index.html | 0001193125-26-430507 |
| Document: 0001193125-26-430507.txt | 0001193125-26-430507 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | 8-K | $2.39 | awaiting T+20 | — | $2.28 (−4.51%) |
Oct 21, 2026 5d ago | 8-K | $3.04 | awaiting T+20 | — | $2.28 (−25.00%) |
Oct 15, 2026 11d ago | SC 13D/A | $2.63 | awaiting T+20 | — | $2.28 (−13.31%) |
Oct 15, 2026 11d ago | SC 13D | $2.63 | awaiting T+20 | — | $2.28 (−13.31%) |
Oct 13, 2026 13d ago | Press Release | $3.03 | awaiting T+20 | — | $2.28 (−24.75%) |
Oct 13, 2026 13d ago | 8-K | $3.03 | awaiting T+20 | — | $2.28 (−24.75%) |
Oct 9, 2026 17d ago | 8-K | $1.05 | awaiting T+20 | — | $2.28 (−117.14%) |
Sep 18, 2026 5w ago | Press Release | $1.20 $2.63 | ▼ −119.17% | ▼ −118.96% | $2.28 (−90.00%) |
Sep 16, 2026 5w ago | 8-K | $1.60 $2.18 | ▲ +36.25% | ▲ +34.79% | $2.28 (+42.50%) |
Jun 29, 2026 17w ago | 8-K | $2.37 $1.94 | ▼ −18.14% | ▼ −17.86% | $2.28 (−3.80%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers